Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2022-06-06 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - HMD 7 pages 29.2KB
Capital/Financing Update Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities (options) by Heramed Limited. It details the number of securities issued, the purpose (payment for advisory services), and compliance with ASX listing rules. There is no indication of financial statements, management discussion, or earnings data. The document is an announcement of a capital issuance event, specifically about securities issuance and related details. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising or capital structure changes.
2022-06-06 English
Notification regarding unquoted securities - HMD 7 pages 29.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted options by Heramed Limited. It includes specifics such as the number of securities issued, issue dates, and the purpose of the issue. The content focuses on the issuance of securities and related compliance with listing rules, without any financial statements or performance data. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues or other capital changes. The document is not a full financial report, earnings release, or regulatory filing of another type, but a specific announcement about securities issuance.
2022-05-04 English
Notification regarding unquoted securities - HMD 7 pages 30.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification about the issue of unquoted equity securities (unlisted options) by Heramed Limited. It includes specifics such as the number of securities issued, exercise price, expiry date, and references to ASX listing rules and shareholder approvals. The content focuses on the issuance of new securities and related regulatory compliance rather than financial results, management changes, or meeting materials. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or capital changes. The document length and detail confirm it is not a brief announcement or a report publication notice, but the actual notification of a capital change event.
2022-05-03 English
Outstanding Results Achieved in Second JHC Clinical Trial 5 pages 216.8KB
Capital/Financing Update Classification · 70% confidence The document is an ASX announcement dated 2 May 2022 from HeraMED Limited. It details the results of a second clinical trial of the HeraBEAT device, focusing on clinical validation, accuracy, usability, and commercial implications. The content is primarily an announcement of clinical trial results and business implications rather than a full financial report or detailed management discussion. There are no financial statements, regulatory certifications, or detailed governance disclosures. The document is lengthy (15,000 characters) and contains detailed clinical trial results and company commentary, but it is structured as a news release or announcement rather than a formal report like an Annual Report (10-K), Interim Report (IR), or Management Discussion & Analysis (MDA). It does not fit into categories like Earnings Release (ER) or Investor Presentation (IP) because it focuses on clinical trial outcomes and product validation rather than financial results or investor strategy. It is not a Regulatory Filing (RNS) because it is a substantive announcement with detailed results, not a compliance or certification document. The best fitting category is Capital/Financing Update (CAP) because the announcement relates to clinical validation that supports the company’s commercialisation strategy and unlocking new business models, which is often linked to capital and financing activities. However, since it is primarily a clinical trial result announcement with commercial implications, and not a direct financing or capital structure update, the confidence is moderate.
2022-05-01 English
Quarterly Activities & Cashflow Report 8 pages 767.9KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 April 2022 providing a quarterly update on HeraMED's commercial strategy, service offerings, and financial overview for Q1 FY22 ending 31 March 2022. It includes detailed financial data such as cash flows from operating, investing, and financing activities, staff costs, marketing expenses, and payments to related parties. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows, confirms this is a quarterly financial report. The document is comprehensive, with substantive financial data and analysis for the quarter, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-28 English
Application for quotation of securities - HMD 6 pages 27.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options or convertible securities into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. There is no financial performance data, management discussion, or audit information. The document is an announcement related to capital changes, specifically the issuance and quotation of new shares following conversion of options. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other filing types.
2022-04-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.